IMPACT BIOMEDICAL INC.
No SEC Form 4 filings for $IBO in the last 30 days.
See all $IBO insider activity →Impact BioMedical (IBO) will execute a 1-for-12.62 reverse stock split on September 23, 2026, to facilitate its merger with Zoar Ltd. The split aims to meet listing standards and support the merger, which will give IBO shareholders one Zoar share for every four IBO shares held. IBO's stock closed at $0.46 on September 11, 2026, and was at $0.43 in pre-market trading.
Dr. Ashleys signs a strategic merger deal to acquire Impact Biomedical in a reverse merger. The combined company will be listed on NYSE American under the name "Dr Ashleys Limited." Get access to the leaderboards pointing to tomorrow's biggest stock movers. Impact Biomedical, Inc.
NEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ( "Dr Ashleys" ) , and Impact BioMedical Inc. ( "Impact BioMedical" ) ( NYSE American: IBO ) , a Texas based biopharmaceuticals developer listed on the New York Stock Exchange ...
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IBO (IMPACT BIOMEDICAL INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IBO coverage spans financial news and corporate actions.
The reverse split aims to meet listing requirements and facilitate the pending merger, potentially improving liquidity and share price perception.
The strategic merger and anticipated listing on NYSE American could positively influence Impact BioMedical's stock, signaling growth prospects and increased investor interest.
The strategic merger between Dr Ashleys Limited and Impact BioMedical Inc. is likely to positively influence Impact BioMedical's stock, potentially leading to increased investor confidence and a short-term price uptick.
AlphAI scores every news story that mentions IBO with an AI model for sentiment and relevance, and aggregates insider trades from IMPACT BIOMEDICAL INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Impact BioMedical (IBO) will execute a 1-for-12.62 reverse stock split on September 23, 2026, to facilitate its merger with Zoar Ltd. The split aims to meet listing standards and support the merger, which will give IBO shareholders one Zoar share for every four IBO shares held. IBO's stock closed at $0.46 on September 11, 2026, and was at $0.43 in pre-market trading.
2 min readDr. Ashleys signs a strategic merger deal to acquire Impact Biomedical in a reverse merger. The combined company will be listed on NYSE American under the name "Dr Ashleys Limited." Get access to the leaderboards pointing to tomorrow's biggest stock movers. Impact Biomedical, Inc.
3 min readNEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ( "Dr Ashleys" ) , and Impact BioMedical Inc. ( "Impact BioMedical" ) ( NYSE American: IBO ) , a Texas based biopharmaceuticals developer listed on the New York Stock Exchange ...
3 min read
